Business Description
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd
ISIN : CNE1000000W4
Share Class Description:
HKSE:01349: Class HCompare
Compare
Traded in other countries / regions
688505.China01349.Hong KongFDY.Germany IPO Date
2002-08-13Description
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd is engaged in the research, development, manufacturing, and sale of biopharmaceutical products. Its product portfolio includes ALA (Aminolevulinic acid Hydrochloride); FuMeiDa and Libord. Geographically, it derives revenue from Mainland China.
Financial Strength
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 69.2 | |||||
| Equity-to-Asset | 0.82 | |||||
| Debt-to-Equity | 0.01 | |||||
| Debt-to-EBITDA | 0.5 | |||||
| Interest Coverage | 33.47 | |||||
| Piotroski F-Score | 4/9 | |||||
| Altman Z-Score | 7.1 | |||||
| Beneish M-Score | -1.96 | |||||
| WACC vs ROIC | ||||||
Growth Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | -3.4 | |||||
| 3-Year EBITDA Growth Rate | -23.2 | |||||
| 3-Year EPS without NRI Growth Rate | -6.5 | |||||
| 3-Year Book Growth Rate | 2.6 |
Momentum Rank
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 61.85 | |||||
| 9-Day RSI | 49.75 | |||||
| 14-Day RSI | 45.65 | |||||
| 6-1 Month Momentum % | -9.35 | |||||
| 12-1 Month Momentum % | -31.17 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 3.7 | |||||
| Quick Ratio | 3.62 | |||||
| Cash Ratio | 2.37 | |||||
| Days Inventory | 554.34 | |||||
| Days Sales Outstanding | 595.68 | |||||
| Days Payable | 101.28 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Dividend Yield % | 3.79 | |||||
| Dividend Payout Ratio | 0.83 | |||||
| 3-Year Dividend Growth Rate | -2 | |||||
| Forward Dividend Yield % | 3.59 | |||||
| 5-Year Yield-on-Cost % | 6.46 | |||||
| Shareholder Yield % | 2.34 |
Profitability Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 91.12 | |||||
| Operating Margin % | 12.67 | |||||
| Net Margin % | 12.26 | |||||
| FCF Margin % | -8.62 | |||||
| ROE % | 1.72 | |||||
| ROA % | 1.34 | |||||
| ROIC % | 4.02 | |||||
| ROC (Joel Greenblatt) % | 6.74 | |||||
| ROCE % | 1.48 | |||||
| Years of Profitability over Past 10-Year | 10 |
GF Value Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PE Ratio | 17.67 | |||||
| PE Ratio without NRI | 22.32 | |||||
| Shiller PE Ratio | 11.78 | |||||
| Price-to-Owner-Earnings | 29.45 | |||||
| PS Ratio | 6.08 | |||||
| PB Ratio | 0.86 | |||||
| Price-to-Tangible-Book | 0.89 | |||||
| Price-to-Operating-Cash-Flow | 28.27 | |||||
| EV-to-EBIT | 128.32 | |||||
| EV-to-EBITDA | 128.32 | |||||
| EV-to-Revenue | 13.82 | |||||
| EV-to-FCF | -155.28 | |||||
| Price-to-Projected-FCF | 0.72 | |||||
| Price-to-DCF (Earnings Based) | 1.93 | |||||
| Price-to-Graham-Number | 0.57 | |||||
| Price-to-Net-Current-Asset-Value | 1.49 | |||||
| Price-to-Net-Cash | 2.99 | |||||
| Earnings Yield (Greenblatt) % | 0.78 | |||||
| FCF Yield % | -0.49 | |||||
| Forward Rate of Return (Yacktman) % | -2.95 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil HK$) | 354.755 | ||
| EPS (TTM) (HK$) | 0.12 | ||
| Beta | 0.63 | ||
| Volatility % | 22.06 | ||
| 14-Day RSI | 45.65 | ||
| 14-Day ATR (HK$) | 0.051248 | ||
| 20-Day SMA (HK$) | 2.1145 | ||
| 12-1 Month Momentum % | -31.17 | ||
| 52-Week Range (HK$) | 2.03 - 3.19 | ||
| Shares Outstanding (Mil) | 1,043 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 4 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd Stock Events
| Event | Date | Price(HK$) | ||
|---|---|---|---|---|
| No Event Data | ||||
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd Frequently Asked Questions
What is Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd(HKSE:01349)'s stock price today?
The current price of HKSE:01349 is HK$2.12. The 52 week high of HKSE:01349 is HK$3.19 and 52 week low is HK$2.03.
When is next earnings date of Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd(HKSE:01349)?
The next earnings date of Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd(HKSE:01349) is .
Does Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd(HKSE:01349) pay dividends? If so, how much?
The Dividend Yield %  of Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd(HKSE:01349) is 3.79% (As of Today), Highest Dividend Payout Ratio of Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd(HKSE:01349) was 0.83. The lowest was 0.21. And the median was 0.39. The  Forward Dividend Yield % of Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd(HKSE:01349) is 3.59%. For more information regarding to dividend, please check our Dividend Page.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers